Received Apr 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 9DF34 | — |
Inappropriate vaccine schedule (early third dose); Inappropriate vaccine schedule (late second dose); This non-serious case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too long in a 38-year-old female patient who received HBV (Engerix B) (batch number 9DF34, expiry date 06-AUG-2028) for prophylaxis. Co-suspect products included HBV (Engerix B) (batch number LZ5X7, expiry date 10-NOV-2027) for prophylaxis. Previously administered products included Engerix B (received 1st dose on 12-SEP-2025 with batch number EB9ZX and lot expiry 10-DEC-2027). On 30-MAR-2026, the patient received the 3rd dose of Engerix B. On 09-MAR-2026, the patient received Engerix B. On 09-MAR-2026, not applicable after receiving Engerix B and an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: Inappropriate vaccine schedule (late second dose)). On 30-MAR-2026, the patient experienced drug dose administration interval too short (Verbatim: Inappropriate vaccine schedule (early third dose)). The outcome of the drug dose administration interval too long and drug dose administration interval too short were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-APR-2026 The reporter was ask was these doses could be considered as valid or have to revaccinate. The vaccine administration facility was the same as primary reporter.